The FDA's budget and the user fees paid by the medtech industry will be affected by the automatic budget cuts known as sequestration, said AdvaMed President Stephen Ubl, who adds that his group is working to make a case about the adverse effects of those cuts. Ubl also expressed concern that political distractions are complicating industry efforts to strike down the medical device tax. "It clearly makes it harder to focus individual members [of Congress] on the harmful impacts of the tax," he said, "[But] I think we’re off to a very strong start this year."
AdvaMed CEO raises concerns over fallout from sequestration
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||